References for A Lifestyle-Based, Functional Health Approach for

the Restoration and Maintenance of Brain Health and Prevention of Cognitive Decline 

  1. https://www.cdc.gov/aging/pdf/cognitive_impairment/cogimp_poilicy_final.pdf
  2. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021 Mar;17(3):327-406.
  3. Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. JAMA. 2021 May 11;325(18):1829-1830. doi: 10.1001/jama.2021.5469.
  4. Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol. 2015 Sep;72(9):1029-42.
  5. James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. Neurology. 2014;82(12):1045-1050.
  6. Si T, Xing G, Han Y. Subjective Cognitive Decline and Related Cognitive Deficits. Front Neurol. 2020 May 19;11:247. doi: 10.3389/fneur.2020.00247. PMID: 32508729; PMCID: PMC7248257. Wolfsgruber S, Kleineidam L, Wagner M, Mösch E, Bickel H, Lϋhmann D, Ernst A, Wiese B, Steinmann S, König HH, Brettschneider C, Luck T, Stein J, Weyerer S, Werle J, Pentzek M, Fuchs A, Maier W, Scherer M, Riedel-Heller SG, Jessen F; AgeCoDe Study Group. Differential Risk of Incident Alzheimer’s Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline. J Alzheimers Dis. 2016 Oct 4;54(3):1135-1146. doi: 10.3233/JAD-160407. PMID: 27567852.
  7. Garcia-Ptacek S, Eriksdotter M, Jelic V, Porta-Etessam J, Kåreholt I, Manzano Palomo S. Subjective cognitive impairment: Towards early identification of Alzheimer disease. Neurologia. 2016 Oct;31(8):562-71.
  8. Reisberg B, Prichep L, Mosconi L, John ER, Glodzik-Sobanska L, Boksay I, Monteiro I, Torossian C, Vedvyas A, Ashraf N, Jamil IA, de Leon MJ. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease. Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S98-S108. doi: 10.1016/j.jalz.2007.11.017. PMID: 18632010.
  9. Si T, Xing G, Han Y. Subjective Cognitive Decline and Related Cognitive Deficits. Front Neurol. 2020 May 19;11:247. doi: 10.3389/fneur.2020.00247. PMID: 32508729; PMCID: PMC7248257.
  10. Cheng YW, Chen TF, Chiu MJ. From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution. Neuropsychiatr Dis Treat. 2017 Feb 16;13:491-498.
  11. Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, Gronseth GS, Marson D, Pringsheim T, Day GS, Sager M, Stevens J, Rae-Grant A. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan 16;90(3):126-135.
  12. Ward A, Tardiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra. 2013 Sep 28;3(1):320-32.
  13. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019 Jul 19;14:5541-5554
  14. Giannopoulos PF, Praticò, D. Alzheimer’s Disease. In: Martin CR, Preedy VR eds., Diet and Nutrition in Dementia and Cognitive Decline. London: Elsevier; 2015: p.38-46.
  15. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21. PMID: 21514250; PMCID: PMC3312024.
  16. Guerreiro R, Bras J. The age factor in Alzheimer’s disease. Genome Med. 2015 Oct 20;7:106.
  17. Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM. Genetics, transcriptomics, and proteomics of Alzheimer’s disease. J Clin Psychiatry. 2006 Apr;67(4):652-70.
  18. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013 Feb;9(2):106-18.
  19. Li Y, Li Y, Li X, Zhang S, Zhao J, Zhu X, Tian G. Head Injury as a Risk Factor for Dementia and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of 32 Observational Studies. PLoS One. 2017 Jan 9;12(1):e0169650.
  20. Nelson AR, Sweeney MD, Sagare AP, Zlokovic BV. Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer’s disease. Biochim Biophys Acta. 2016 May;1862(5):887-900.
  21. Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L, Erkinjuntti T, Mäkelä M, Oinas M, Paetau A, Scheltens P, van Straaten EC, Sulkava R, Solomon A. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain. 2013 Sep;136(Pt 9):2707-16.
  22. Huang CC, Chung CM, Leu HB, Lin LY, Chiu CC, Hsu CY, Chiang CH, Huang PH, Chen TJ, Lin SJ, Chen JW, Chan WL Diabetes mellitus and the risk of Alzheimer’s disease: a nationwide population-based study. PLoS One. 2014 Jan 29;9(1):e87095.
  23. Machado A, Herrera AJ, de Pablos RM, Espinosa-Oliva AM, Sarmiento M, Ayala A, Venero JL, Santiago M, Villarán RF, Delgado-Cortés MJ, Argüelles S, Cano J. Chronic stress as a risk factor for Alzheimer’s disease. Rev Neurosci. 2014;25(6):785-804.
  24. Glenner GG. Alzheimer’s disease. The commonest form of amyloidosis. Arch Pathol Lab Med. 1983 Jun;107(6):281-2.
  25. Glenner GG. The pathobiology of Alzheimer’s disease. Annu Rev Med. 1989;40:45-51.
  26. Liu PP, Xie Y, Meng XY, Kang JS. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduct Target Ther. 2019 Aug 23;4:29. doi: 10.1038/s41392-019-0063-8. Erratum in: Signal Transduct Target Ther. 2019 Sep 23;4:37. PMID: 31637009; PMCID: PMC6799833.
  27. Kurkinen M. The amyloid hypothesis is too good to be true. Alzheimers Dement Cogn Neurol. 2017; 1(1): 1-9.
  28. Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021 Apr;17(4):696-701. doi: 10.1002/alz.12213. Epub 2020 Nov 1. PMID: 33135381.
  29. Pagliarulo N. Aducanumab’s failure puts pressure on field to look beyond amyloid [Internet]. Washington, DC. BioPharma Dive. 2019 March [cited August 19, 2021]. Available from: https://www.biopharmadive.com/news/aducanumabs-failure-puts-pressure-on-field-to-look-beyond-amyloid/551071/
  30. Mullard A. Landmark Alzheimer’s drug approval confounds research community. Nature. 2021 Jun;594(7863):309-310.
  31. Bredesen DE. Reversal of cognitive decline: a novel therapeutic program. Aging (Albany NY). 2014 Sep;6(9):707-17.
  32. Bredesen DE, Amos EC, Canick J, Ackerley M, Raji C, Fiala M, Ahdidan J. Reversal of cognitive decline in Alzheimer’s disease. Aging (Albany NY). 2016 Jun;8(6):1250-8.
  33. Bredesen, DE. The end of Alzheimer’s. New York: Avery; 2017: p. 55-92.